A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
REMIND tested a BTK inhibitor in three CIndU subtypes using objective, subtype-specific provocation tests. Understanding how ...
Eingun James Song, MD, reviews the risks of under-treating pediatric atopic dermatitis and post hoc growth data with dupilumab.
New HS treatment guidelines emphasize expanded biologic options, individualized care, and early intervention to prevent irreversible damage.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
Mark Lebwohl, MD, reviews the safety, dosing, and efficacy of oral TYK2 inhibitors and icotrokinra in psoriasis.
Cost and insurance coverage, not efficacy alone, ultimately determined this patient's treatment course. His account of near ...
BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active ...
A high-risk molecular result can change management in thin and node-negative melanoma. Dr. Singh explains how GEP findings shape sentinel node biopsy, imaging, and surveillance decisions.
A patient describes losing most of her hair in a single shower, then being told it was stress. Her account shows how dismissal delays diagnosis and treatment of an autoimmune disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results